- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Do | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum | 82 | ACCESS Newswire | Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical... ► Artikel lesen | |
| Mi | CNSP-Aktie erreicht 52-Wochen-Tief bei 0,08 US-Dollar | 1 | Investing.com Deutsch | ||
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mi | CNS Pharmaceuticals to implement 1-for-50 reverse stock split | 3 | Seeking Alpha | ||
| Mi | CNS Pharmaceuticals, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference | 131 | ACCESS Newswire | On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing... ► Artikel lesen | |
| Mi | CNS Pharmaceuticals enacts 1-for-50 reverse stock split | 2 | Investing.com | ||
| Mi | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Reverse Stock Split | 167 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments... ► Artikel lesen | |
| Di | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit | 221 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments... ► Artikel lesen | |
| 10.02. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference | 209 | ACCESS Newswire | In-person presentation today, February 10th at 1:15 PM ET HOUSTON, TX / ACCESS Newswire / February 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| 03.01. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 11.12.24 | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 05.12.24 | CNS Pharmaceuticals sets date for virtual investor event | 2 | Investing.com | ||
| 05.12.24 | CNS Pharmaceuticals veranstaltet am 11. Dezember 2024 den "Virtual Analyst & Investor Day" | 245 | IR-WORLD | Live-Webcast-Diskussion mit international anerkannten Meinungsbildnern auf dem Gebiet von Glioblastoma Multiforme
(GBM)
Das Unternehmen widmet sich mit großem Engagement der aggressivsten... ► Artikel lesen | |
| 05.12.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 | 292 | ACCESS Newswire | Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion LeadersCompany committed to addressing the most aggressive type of brain cancer with an average survival... ► Artikel lesen | |
| 03.12.24 | CNS Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM After Failure of Standard First Line Therapy | 347 | ACCESS Newswire | Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half... ► Artikel lesen | |
| 18.11.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology | 177 | ACCESS Newswire | HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
| 15.11.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results | 292 | ACCESS Newswire | Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company strengthens cash position to extend runway to fund operations beyond data... ► Artikel lesen | |
| 14.11.24 | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11.24 | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment | 389 | ACCESS Newswire | Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael WellerAccess the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc.... ► Artikel lesen |
Seite:
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,170 | +0,70 % | EQS-News: CureVac erneut von LexisNexis® als eines der weltweit führenden Innovationsunternehmen ausgezeichnet | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erneut von LexisNexis® als eines der weltweit führenden Innovationsunternehmen ausgezeichnet
18.02.2025... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,965 | +1,47 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| BIOXXMED | 0,920 | -3,36 % | EQS-Adhoc: bioXXmed AG: bioXXmed beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
21.02.2025 / 16:57 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ORGANOVO | 0,355 | +1,00 % | ORGANOVO HOLDINGS, INC. - 10-Q, Quarterly Report | ||
| OCUGEN | 0,657 | +0,69 % | Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410-a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control armsPhase 1/2 study (N=60) demonstrated favorable safety and tolerability profile with no serious adverse... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,041 | +6,58 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| BIO-GATE | 0,750 | -3,85 % | EQS-News: Bio-Gate AG: Bio-Gate bringt über Partner weitere Produktlinie zum Schutz von Haut- und Hufarealen bei Pferden auf den Markt | EQS-News: Bio-Gate AG
/ Schlagwort(e): Produkteinführung/Vorläufiges Ergebnis
Bio-Gate bringt über Partner weitere Produktlinie zum Schutz von Haut- und Hufarealen bei Pferden... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,842 | -8,68 % | Defence Therapeutics Inc.: Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million | Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing... ► Artikel lesen | |
| VAXART | 0,689 | +0,73 % | Vaxart, Inc.: Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial | Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data The company plans to progress the... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,071 | +11,56 % | Burcon NutraScience Corporation: Burcon Announces Details of $9.43 Million Rights Offering | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| AFFIMED | 0,952 | -3,64 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,310 | +1,31 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| IMMUNIC | 1,237 | +2,57 % | EQS-News: Immunic AG: Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing | Issuer: Immunic AG
/ Key word(s): Study results
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,129 | -3,73 % | AIM ImmunoTech Highlights Higher Post-COVID Prevalence Of Myalgic Encephalomyelitis/Chronic Fatigue | WASHINGTON (dpa-AFX) - AIM ImmunoTech Inc. (AIM), Wednesday revealed 15 times increase in incidence of Myalgic encephalomyelitis or ME/ Chronic Fatigue Syndrome or CFS in patients infected with... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen |
CNS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
